Back

Elegibility for Sacubitril/Valsartan in italian clinical practice: insights from the OPTIMA-HF registry

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Stefania Paolillo

University of Naples Federico II, Naples (Italy)

7 More presentations in this session

Presentation thumbnail
Guideline-directed medical therapy patterns in heart failure with reduced ejection fraction: the OPTIMA-HF registry
Doctor S. Paolillo (Naples, IT)
Abstract Slides
Presentation thumbnail
Quality of life in patients with heart failure and improved ejection fraction: one-year follow-up with ARNI and SGLT2i
Professor S. Tadic (Novi Sad, RS)
Abstract Slides
Presentation thumbnail
Real world evidence of Sacubitril/Valsartan in octogenarian patients with heart failure. Results From the PARACHUTE-HF Study
Doctor N. Okuda (Kawagoe, JP)
Abstract Slides
Presentation thumbnail
Estimated plasma volume in heart failure with reduced ejection fraction: ACE inhibitors versus angiotensin receptor/neprilysin inhibitor in follow up
Doctor S. Varga (Sisak, HR)
Abstract Slides
Presentation thumbnail
Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i
Mrs O. Obertynska (Vinnitsa, UA)
Abstract Slides

Access the full session

Session thumbnail
Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources